Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Grit Biotechnology has developed proprietary platforms for rapid and efficient expansion of tumor-infiltrating lymphocytes with enhanced memory phenotype, enabling next-generation gene-edited cell therapies for solid tumors. Their technology allows large-scale production with high consistency and cost advantages. Early clinical results show successful manufacturing in multiple indications with promising efficacy signals. The company recently presented scientific breakthroughs at ASGCT 2025 and closed a $60 million Series B financing round to advance its pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on TheRealGrit.